This reports provides a data-driven overview of the current and future competitive landscape in AS therapeutics.
- There will be more than 313,981 diagnosed prevalent cases of AS in 2023 in the 16 major markets
- The marketed drugs space for AS is poor as there are no therapies currently approved for the treatment of the disease
- R&D activity in AS is very sparse, with only one drug in late-stage development
- Commercial sponsors dominated the clinical trials space in AS over the past 10 years, with Ovid Therapeutics sponsoring the highest number of clinical trials
- During the past 12 months, three merger and acquisition transactions involving companies developing AS assets were successfully completed
Scope
The publisher's Angelman Syndrome: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.Components of the report include:
- Disease Landscape
- Disease Overview
- Epidemiology Overview
- Treatment Overview
- Marketed Products Assessment
- Breakdown by Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Pricing and Reimbursement Assessment
- Annual Therapy Cost
- Time to Pricing and Time to Reimbursement
- Pipeline Assessment
- Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Late-to-mid-stage Pipeline Drugs
- Phase Transition Success Rate and Likelihood of Approval
- Clinical Trials Assessment
- Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
- Enrolment Analytics, Site Analytics, Feasibility Analysis
- Deals Landscape
- Mergers, Acquisitions, and Strategic Alliances by Region
- Overview of Recent Deals
- Commercial Assessment
- Key Market Players
- Future Market Catalysts
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline
- Develop business strategies by understanding the trends shaping and driving the AS market
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global AS market in the future
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships
Table of Contents
1 Preface
3 Disease Landscape
4 Marketed Drugs Assessment
6 Pipeline Drugs Assessment
7 Clinical Trials Assessment
8 Deals Landscape
9 Commercial Assessment
11 Appendix
Related Reports
Alcoholic Hepatitis: Competitive Landscape
- Report
- 65 Pages
- Global
From
Focal Segmental Glomerulosclerosis: Competitive Landscape
- Report
- 76 Pages
- Global
From
Angelman Syndrome - Pipeline Insight, 2024
- Clinical Trials
- 60 Pages
- Global
From
From
From
This product is a market research report. Each license type allows a set number of users to access the report. Please select an option from the list below. This product is a market research report. This is a single user license, allowing one user access to the product. The product is a PDF. This product is a market research report. This is a site license, allowing all users within a given geographical location of your organization access to the product. The product is a PDF. This product is a market research report. This is an enterprise license, allowing all employees within your organization access to the product. The product is a PDF. 
